Chunyu Li, Sichuan University, China Updates Copyright 2023 Zhang, Li, Zhao, Shu, Luo, Li, Ding, Shi, Cheng and Niu
The medication works by mimicking a hormone that regulates hunger signals in the brain
GLP-1 RA progress: REMODEL, SURPASS-CVOT By Joel Topf When the history of GLP-1 RAs in kidney disease is finally written, 2024 will always be the highlight, because of the central importance of the FLOW trial (Number 1 on last years Top Stories)
This means that even if a capsule contains 500mg of the ingredient, only a tiny fraction might actually be absorbed as a whole molecule
Sources: the REDEFINE 1 program (obesity, n3417) and REDEFINE 2 (type 2 diabetes, n1206) for the cagrilintide + semaglutide combination (NEJM 2025)